Fig 3.
Meta-analysis of anticoagulation studies evaluating the impact on mortality in cancer patients without venous thrombosis: 1-year overall mortality by type of anticoagulation. SCLC, small-cell lung cancer; LMWH, low molecular weight heparin; UFH, unfractionated heparin; NSCLC, non–small-cell lung cancer; CRC, colorectal cancer; HN, head and neck cancer. Adapted from Kuderer et al.176